1. Home
  2. NVAX vs SDGR Comparison

NVAX vs SDGR Comparison

Compare NVAX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVAX
  • SDGR
  • Stock Information
  • Founded
  • NVAX 1987
  • SDGR 1990
  • Country
  • NVAX United States
  • SDGR United States
  • Employees
  • NVAX N/A
  • SDGR N/A
  • Industry
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • SDGR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVAX Health Care
  • SDGR Health Care
  • Exchange
  • NVAX Nasdaq
  • SDGR Nasdaq
  • Market Cap
  • NVAX 1.3B
  • SDGR 1.4B
  • IPO Year
  • NVAX 1995
  • SDGR 2020
  • Fundamental
  • Price
  • NVAX $7.98
  • SDGR $18.65
  • Analyst Decision
  • NVAX Buy
  • SDGR Buy
  • Analyst Count
  • NVAX 7
  • SDGR 7
  • Target Price
  • NVAX $14.29
  • SDGR $28.43
  • AVG Volume (30 Days)
  • NVAX 7.2M
  • SDGR 1.2M
  • Earning Date
  • NVAX 11-11-2025
  • SDGR 11-11-2025
  • Dividend Yield
  • NVAX N/A
  • SDGR N/A
  • EPS Growth
  • NVAX N/A
  • SDGR N/A
  • EPS
  • NVAX 2.54
  • SDGR N/A
  • Revenue
  • NVAX $1,078,718,000.00
  • SDGR $237,917,000.00
  • Revenue This Year
  • NVAX $61.69
  • SDGR $23.71
  • Revenue Next Year
  • NVAX N/A
  • SDGR $21.80
  • P/E Ratio
  • NVAX $3.25
  • SDGR N/A
  • Revenue Growth
  • NVAX 9.22
  • SDGR 18.59
  • 52 Week Low
  • NVAX $5.01
  • SDGR $16.60
  • 52 Week High
  • NVAX $15.22
  • SDGR $28.47
  • Technical
  • Relative Strength Index (RSI)
  • NVAX 51.06
  • SDGR 41.63
  • Support Level
  • NVAX $7.63
  • SDGR $18.13
  • Resistance Level
  • NVAX $8.31
  • SDGR $19.71
  • Average True Range (ATR)
  • NVAX 0.35
  • SDGR 0.67
  • MACD
  • NVAX -0.00
  • SDGR -0.03
  • Stochastic Oscillator
  • NVAX 65.20
  • SDGR 22.91

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

About SDGR Schrodinger Inc.

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.

Share on Social Networks: